Neurocrine Biosciences has a fifty-two week low of $105.18 and a fifty-two week high of $157.98. The firm has a market capitalization of $10.87 billion, a P/E ratio of 33.13, a P/E/G ratio of 0.77 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Make it happen here. Located in the heart of the City of London, our European headquarters is the first wholly owned and designed Bloomberg building in the world. Designed to facilitate ...

After hours: March 17 at 4:20:00 PM EDT Loading Chart for NBIX ...

Elysse Bell is a finance and business writer for Investopedia. She writes about small business, personal finance, technology, and more. Katie Miller is a consumer financial services expert. She ...

• Corporate actions are actions taken by a company that impact the shareholders’ value directly. It is an event that brings material changes to a company and affects its stakeholders ...